Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Musa Yilmaz

Showing results (61-70 of 160) with videos related to

Pageof 16
Sort By:
Blood Advances|February 28, 2025
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemiaFarhad Ravandi, Sravanti Rangaraju, Hagop Kantarjian, et al.
Cancer|June 1, 2019
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemiaKamal Chamoun, Hagop M Kantarjian, Xuemei Wang, et al.
Cancer|March 18, 2025
A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemiaAlexandre Bazinet, Alex Bataller, Tapan Kadia, et al.
Journal of Hematology & Oncology|June 16, 2021
Impact of frontline treatment approach on outcomes of myeloid blast phase CMLKapil Saxena, Elias Jabbour, Ghayas Issa, et al.
Cancer|May 4, 2018
Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemiaKiran Naqvi, Elias Jabbour, Jeffrey Skinner, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 10, 2020
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic LeukemiaGuillaume Richard-Carpentier, Elias Jabbour, Nicholas J Short, et al.
American Journal of Hematology|July 24, 2023
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib eraFadi G Haddad, Koji Sasaki, Aram Bidikian, et al.
Blood Advances|August 30, 2023
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemiaFarhad Ravandi, Asad Bashey, James Foran, et al.
The Lancet. Haematology|October 24, 2022
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Peptides|March 1, 2014
Irisin: a potentially candidate marker for myocardial infarctionTuncay Kuloglu, Suna Aydin, Mehmet Nesimi Eren, et al.
Pageof 16

Showing results (61-70 of 160) with videos related to

Sort By:
Pageof 16
Blood Advances|February 28, 2025
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemiaFarhad Ravandi, Sravanti Rangaraju, Hagop Kantarjian, et al.
Cancer|June 1, 2019
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemiaKamal Chamoun, Hagop M Kantarjian, Xuemei Wang, et al.
Cancer|March 18, 2025
A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemiaAlexandre Bazinet, Alex Bataller, Tapan Kadia, et al.
Journal of Hematology & Oncology|June 16, 2021
Impact of frontline treatment approach on outcomes of myeloid blast phase CMLKapil Saxena, Elias Jabbour, Ghayas Issa, et al.
Cancer|May 4, 2018
Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemiaKiran Naqvi, Elias Jabbour, Jeffrey Skinner, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 10, 2020
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic LeukemiaGuillaume Richard-Carpentier, Elias Jabbour, Nicholas J Short, et al.
American Journal of Hematology|July 24, 2023
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib eraFadi G Haddad, Koji Sasaki, Aram Bidikian, et al.
Blood Advances|August 30, 2023
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemiaFarhad Ravandi, Asad Bashey, James Foran, et al.
The Lancet. Haematology|October 24, 2022
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Peptides|March 1, 2014
Irisin: a potentially candidate marker for myocardial infarctionTuncay Kuloglu, Suna Aydin, Mehmet Nesimi Eren, et al.
Pageof 16